TheranosticTrials.org

Clinical Trial · NCT02307630

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Overview

The purpose of this study is to find out how an antibody called Hu3F8 travels through the body and to tumors. Antibodies, like Hu3F8, are proteins that help attack tumors or fight infections. Antibodies can be made by your own body or in a laboratory. The target of an antibody is called an antigen; antibodies fit their antigen like a lock fits a key.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

N/A

Contacts

Shakeel Modak, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02307630

Drug / Compound

Hu3F8

Isotope(s):
Target(s):
  • GD2
Ligand Class: Antibodies

Eligibility

Inclusion

  • Have one of the following diagnoses (these tumors are known to express GD2 on cell surface):
  • Patients with tumors other than neuroblastoma must meet both the following criteria:
  • Relapsed or refractory stage 4 disease or relapsed or refractory stage MYCN-amplified 2B or 3 disease.
  • Diagnosis confirmed by histological assessment by MSKCC Department of pathology or by the presence of BM metastases PLUS elevated urinary catecholamines
  • * Patients with the diagnosis of neuroblastoma must meet both of the following criteria:

Exclusion

  • Inability to comply with protocol requirements.
  • * Existing major organ dysfunction \> grade 2, with the exception of myelosuppression (neutrophil count \> or = 500/μl and platelet count \> or = 25,000/μl are acceptable) and hearing loss.
  • Acute life threatening infection
  • Requirement for sedation for PET/CT scans
  • Pregnant women or women who are breast-feeding.